Published in Br J Pharmacol on June 01, 2010
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br J Pharmacol (2012) 0.95
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol (2012) 0.93
Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol (2012) 0.89
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol (2013) 0.89
Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci (2016) 0.86
β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic Biol Med (2012) 0.85
Update on the role of cannabinoid receptors after ischemic stroke. Mediators Inflamm (2012) 0.85
Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist. Mol Pain (2013) 0.82
Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem (2012) 0.81
The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J (2013) 0.81
The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS One (2013) 0.80
The Role of the Endocannabinoid System in the Brain-Gut Axis. Gastroenterology (2016) 0.78
Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur J Pharmacol (2014) 0.76
Potential effects of cannabidiol as a wake-promoting agent. Curr Neuropharmacol (2014) 0.76
Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development. Evid Based Complement Alternat Med (2015) 0.76
An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front Pharmacol (2017) 0.75
Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation? Br J Pharmacol (2016) 0.75
Themed issue: cannabinoids. Br J Pharmacol (2010) 0.75
Endocannabinoids: A Promising Impact for Traumatic Brain Injury. Front Pharmacol (2017) 0.75
Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol (2009) 8.07
Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov (2008) 3.93
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol (2007) 2.08
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer (2004) 1.97
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Brain cannabinoids in chocolate. Nature (1996) 1.78
Cannabinoid pharmacology: the first 66 years. Br J Pharmacol (2006) 1.73
The enigmatic pharmacology of GPR55. Trends Pharmacol Sci (2009) 1.68
Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett (1995) 1.57
Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem (2006) 1.54
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem (2010) 1.49
Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol (2007) 1.42
How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. J Ethnopharmacol (2009) 1.39
Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.26
Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol (2009) 1.09
Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res (2010) 1.07
Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil (2009) 1.05
Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol (2008) 1.04
Absorption of kaempferol from endive, a source of kaempferol-3-glucuronide, in humans. Eur J Clin Nutr (2004) 1.03
In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med (2008) 1.02
Effects of triterpenes on the immune system. J Ethnopharmacol (2010) 1.01
Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol (2009) 1.01
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology (2009) 0.99
Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol (2009) 0.96
Role for PPARgamma in IL-2 inhibition in T cells by Echinacea-derived undeca-2E-ene-8,10-diynoic acid isobutylamide. Int Immunopharmacol (2009) 0.94
Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? J Pharm Pharmacol (2009) 0.94
Plant fatty acid (ethanol) amide hydrolases. Biochim Biophys Acta (2006) 0.90
The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol (2007) 0.88
Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. Br J Pharmacol (2008) 0.87
Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. Biochem Pharmacol (2010) 0.86
Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action? Commun Integr Biol (2008) 0.84
New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. J Recept Signal Transduct Res (2006) 0.84
Trick or treat from food endocannabinoids? Nature (1998) 0.84
Polyphenols: biological activities, molecular targets, and the effect of methylation. Curr Mol Pharmacol (2008) 0.84
Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans. Planta Med (2008) 0.83
Retracted The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. J Pharmacol Exp Ther (2009) 0.81
An examination of anthocyanins' and anthocyanidins' affinity for cannabinoid receptors. J Med Food (2009) 0.79
Notice of retraction. J Pharmacol Exp Ther (2009) 0.78
Interview with Prof. Raphael Mechoulam, codiscoverer of THC.. Interview by Stanley Einstein. Int J Addict (1986) 0.77
Tea catechins' affinity for human cannabinoid receptors. Phytomedicine (2009) 0.77
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem (2004) 1.87
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Endocannabinoids and the control of energy balance. Trends Endocrinol Metab (2006) 1.74
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab (2013) 1.67
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Biochemistry and pharmacology of endovanilloids. Pharmacol Ther (2007) 1.64
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol (2005) 1.60
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res (2008) 1.60
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol (2009) 1.55
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2006) 1.54
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 1.52
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem (2003) 1.48
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A (2008) 1.47
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr (2009) 1.39
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 1.38
Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci (2006) 1.37
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab (2009) 1.36
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology (2005) 1.33
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta (2006) 1.31
Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol (2002) 1.31
Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol (2006) 1.30
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol (2003) 1.30
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol (2008) 1.30
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol (2007) 1.30
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol (2003) 1.29
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed Engl (2011) 1.26
The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav (2005) 1.25
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther (2008) 1.25
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 1.24
Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol (2002) 1.24
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol (2004) 1.24
Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem (2002) 1.22
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology (2008) 1.21
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res (2005) 1.21
TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des (2008) 1.21
Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci (2007) 1.20
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie (2010) 1.19
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010) 1.19
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol (2009) 1.17
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem (2008) 1.16
Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 1.16
Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol (2007) 1.15
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J (2003) 1.15
Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med (2012) 1.15
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res (2007) 1.14
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2006) 1.14
Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther (2002) 1.13
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) (2007) 1.12
Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci (2009) 1.12
Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod (2002) 1.12
DAG lipase involvement in depolarization-induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand? Neuroscientist (2010) 1.12
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem (2011) 1.11
Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun (2005) 1.11
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol (2004) 1.10
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des (2002) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med (2005) 1.09
Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med (2002) 1.09
Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol (2009) 1.09
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol (2004) 1.09
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis (2010) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A (2009) 1.08
Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol (2009) 1.08
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis (2010) 1.08
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl) (2007) 1.07
Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res (2010) 1.07